Acute presentations in neoadjuvant chemotherapy/immune checkpoint inhibition for triple negative breast cancer: experiences and impact from real-world data
Open Access
- 15 July 2025
- journal article
- Published by Elsevier in The Breast
- Vol. 83, 104536
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Real-World Immune-Related Adverse Events in Patients With Early Triple-Negative Breast Cancer Who Received PembrolizumabJCO Oncology Practice, 2025
- Low-risk febrile neutropenia: does combined chemotherapy/immune checkpoint inhibitor necessitate a change in approach?Supportive Care in Cancer, 2025
- Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast CancerNew England Journal of Medicine, 2022
- Event-free Survival with Pembrolizumab in Early Triple-Negative Breast CancerNew England Journal of Medicine, 2022
- MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitorsSupportive Care in Cancer, 2020
- Emergency presentations in patients treated with immune checkpoint inhibitorsEuropean Journal of Cancer, 2020
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2018
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- NEWSDIG: The National Early Warning Score Development and Implementation GroupClinical Medicine, 2012